Clinical Trial Update: Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes ongoing Phase 1/Phase 2 studies evaluating the safety and efficacy of LPM3770164 sustained-release tablets in patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• LPM3770164 sustained-release tablets (LPM3770164)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Tardive Dyskinesia (TD) | Phase 1, Phase 2 | Status: RECRUITING